Biohit

2,57

EUR

−3,49 %

4 837 följer bolaget

BIOBV

NASDAQ Helsinki

Medicinsk Utrustning & Service

Hälsovård

Översikt

Nyckeltal & Estimat

Investerarkonsensus

−3,49%

−12,88%

−23,51%

+12,23%

+10,3%

+25,37%

+62,66%

−12,29%

−50,58%

Biohit är verksamt inom medicinteknik. Bolaget utvecklar och tillverkar laboratorieutrustning, förnödenheter samt diagnostiska analyssystem anpassade för forskning, vård och industrilaboratorium. Utöver huvudverksamheten erbjuds teknisk support, underhåll samt utbildningstjänster inom nämnt arbetsområde. Störst verksamhet återfinns inom den nordiska marknaden. Bolaget har sitt huvudkontor i Helsingfors.

Börsvärde

39,02 mn EUR

Omsatt (värde)

77,92 tn EUR

P/E (just.) (25e)

17,13

EV/EBIT (adj.) (25e)

12,2

P/B (25e)

2,68

EV/S (25e)

1,82

Direktavkastnings- % (25e)

1,46 %

Coverage

Rekommendation

Öka

Riktkurs

3.20 EUR

Uppdaterad

2025-03-02

Antti Siltanen

Analytiker

Senaste analysen

Latest analysis report

Released: 2025-03-03

Latest extensive report

Released: 2025-01-15

Omsättning & EBIT-%

Omsättning mn

EBIT-%

Vinst per aktie & Utdelning

EPS (adj.)

Direktavkastning

Finansiell kalender

4/6

2025

Bolagsstämma '25

6/8

2025

Delårsrapport Q2'25

Risk

Business risk

Valuation risk

Låg

Hög

Alla

Analys

Pressmeddelanden

VisarAlla typer av innehåll

Regulatoriskt pressmeddelande2025-03-25 10:10

Biohit Plc - Managers' transactions - Hendolin

Regulatoriskt pressmeddelande2025-03-19 07:30

Publication of Biohit Oyj Annual Report 2024

Regulatoriskt pressmeddelande2025-03-19 07:30

Publication of Biohit Oyj Remuneration Report 2024

Välkommen med i Inderes community!

Skapa ett gratis användarkonto och försäkra dig om att inte missa några börsnyheter av intresse för precis dig!

Inderes användarkonto

Ger dig möjlighet att följa bolag och beställa notifikationer

Tillgång till analytikerkommentarer och rekommendationer

Tillgång till vårt aktiescreeningsverktyg och andra populära verktyg

Skapa användarkonto

Regulatoriskt pressmeddelande2025-03-13 13:32

Biohit Oyj - Managers' Transactions

Biohit: Safety margin available again

Aktieanalys2025-03-03 09:15 av

Biohit: Safety margin available again

Biohit's share price has fallen and the risk/reward ratio has become attractive again.

Biohit H2'24: Progress despite a bumpy road

Aktieanalys2025-02-13 07:41 av

Biohit H2'24: Progress despite a bumpy road

Biohit's figures were already largely known based on preliminary data and the H2 report was in line with expectations.

Regulatoriskt pressmeddelande2025-02-12 07:30

BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2024

Biohit H2’24 preview: Growth subdued in H2, but profitability excellent

Analytikerkommentar2025-02-11 07:13 av

Biohit H2’24 preview: Growth subdued in H2, but profitability excellent

Based on releases in recent months, we expect growth from the launch of the new product, distribution partnerships and a new market opening around the middle of the year, referred to by the company in its Q3’24 IR blog.

Pressmeddelande2025-02-06 09:00

BIOHIT and Restalyst announce collaboration to improve non-invasive early gastric cancer detection

Pressmeddelande2025-01-31 09:30

BIOHIT introduces the FAEX™ Sample System for stool sample collection and handling

Analytikerkommentar2025-01-17 07:07 av

New distribution rights for Biohit

Biohit announced on Thursday that it has signed a distribution agreement with Biomedal for the distribution of celiac disease diagnostic tests in selected European countries.

Pressmeddelande2025-01-16 09:00

BIOHIT secures European distribution rights for Biomedal’s gluten immunogenic peptide tests

Omfattande aktieanalys2025-01-15 12:56 av

Biohit extensive report: Profitable growth through diagnostics

Biohit has achieved a successful turnaround and is targeting strong growth of 15-20% over the 2024-28 strategy period. We expect the company's earnings to continue to grow in the coming years, supported by the development of new markets and new product launches.

Analytikerkommentar2025-01-09 06:53 av

Biohit test receives further proof of its effectiveness in the UK

Biohit announced on Wednesday the results of a study of GastroPanel® for the diagnosis of gastric precancerous conditions. The GastroPanel® test on a blood sample identified patients at risk of gastric cancer requiring further examinations with over 90% accuracy.

Pressmeddelande2025-01-08 08:30

Approval of Biohit’s GastroPanel® test for use by the British National Health Service (NHS) takes a major step forward

Aktieanalys2024-12-23 06:50 av

Biohit: Performance surprised positively

Biohit issued a profit warning related to revenue, but despite this, the new 2024 earnings guidance (EBIT percentage 16-18%) clearly exceeded our expectations.

Analytikerkommentar2024-12-20 06:50 av

Positive earnings surprise revealed under Biohit revenue guidance downgrade

Profitability has seen some ups and downs, so the sustainability of H2's excellent performance is still uncertain.

Regulatoriskt pressmeddelande2024-12-19 09:00

Insider information, profit warning: Biohit lowers its guidance for 2024

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Video2024-12-02 14:00

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia Technologies BBS-Bioactive Bone Substitutes Bioretec Biohit Faron Pharmaceuticals Modulight Nexstim Orion Bittium Detection Technology Optomed Revenio Group Nightingale Health Herantis Pharma Nanoform Finland

Regulatoriskt pressmeddelande2024-11-27 12:00

Biohit Oyj’s Financial Reporting and Annual General Meeting in 2025

Forum uppdateringar

Biohits aktiekurs har sjunkit, vilket har gjort värderingen mer attraktiv. Bolagets utsikter har inte förändrats, och Inderes förväntar sig tillväxt från nya produkter samt marknadsöppningar. Situationen i Mellanöstern och förändringar i försäljningsmixen kan dock medföra osäkerhet...

2025-03-03 15:02

by börsen84

2

Nedan är en analytikers skrivelse om Biohits senaste uppdateringar. Biohit that reports semi-annually does not publish business reviews for Q1 and Q3, but the company reports on its progress on the IR blog. The Q3 blog did not comment on progress against financial targets this time...

2024-10-10 08:47

by börsen84

2

I fredags meddelade Biohit att de kommer att förändra sin organisation för att stärka företagets strategiska och operativa prestation inom forskning och utveckling. Och här är en analytikers tankar om detta. Inderes Biohit strengthens R&D - Inderes On Friday, Biohit announced that...

2024-06-17 10:43

by börsen84

2

Detta meddelande gladde investerarna BIOHIT and Restalyst announce collaboration to improve non-invasive early gastric cancer detection Biohit Oyj Press release 6 February 2025 at 11.00 am local time (EEST) BIOHIT Oyj, a pioneer in non-invasive diagnostics for gastrointestinal diseases...

2025-02-09 22:03

by börsen84

0

Here is a fresh comment from an analyst regarding yesterday’s “news.” Biohit announced on Thursday that it has signed a distribution agreement with Biomedal for the distribution of celiac disease diagnostic tests in selected European countries. The distribution agreement complements...

2025-01-17 07:20

by börsen84

0

Here is a high-quality, comprehensive, and easy-to-read analysis/report on this company in a very interesting “situation.” Biohit is focused on diagnostics of the gastrointestinal tract and health-promoting products. The company has achieved a successful turnaround and is targeting...

2025-01-16 07:13

by börsen84

0

Biohit’s GastroPanel® test demonstrated over 90% accuracy in identifying patients at risk of gastric cancer, confirming results from previous studies. The study conducted at Homerton Hospital may facilitate the test’s adoption in the UK NHS, supporting Biohit’s target of 15–20% annual...

2025-01-09 21:46

by börsen84

0

Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.